Summaries by Inventor DeSelm, Carl
DeSelm, Carl
T-019199
— Published date: 6/2/2026 Value proposition: CAR-engineered cDC1 cells (syngeneic or allogeneic) that stably express a proprietary, modular chimeric antigen receptor and demonstrate strong in vivo efficacy against solid tumors, including immunologically ‘cold’ tumors. Technology Desc…
Novel Cell Therapy Platform for Cancer using Engineered cDC1 Dendritic CellsDeSelm, Carl ; Namen, Shelby ; Pandey, Gaurav
T-020903
— Published date: 5/30/2026 Value Proposition: CAR-engineered cDC1 cells (syngeneic or allogeneic) that stably express a proprietary, modular chimeric antigen receptor and demonstrate strong in vivo efficacy against solid tumors, including immunologically ‘cold’ tumors. Technology Descr…
CAR Macrophages for Targeted Degradation of Pathogenic SubstancesDeSelm, Carl ; Diwan, Abhinav ; Lee, Jin-Moo
T-020543
— Published Date: 5/14/2025 Value proposition: Self-sustaining chimeric macrophages as a novel approach to target amyloid plaques resulting in improved efficacy and survival in patients. Technology Description Researchers from Washington University in St. Louis have engineered macrophages to expre…
